News
Teleperformance: Launch of a Share Buyback Program for 150 Million Euros Following the Disproportionate Decline in the Share Price
Regulatory News:
Teleperformance Group's (Paris:TEP) executive management has requested a brief suspension of its listing following the sell-off caused by the announcement in certain media by the
Valbiotis lanciert Kapitaleinwerbung von rund 8 Mio. Euro zur Beschleunigung seiner Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
BILENDI: Revenues for the 3rd quarter of 2022: +41.9%
Valbiotis schließt Finanzierungsrunde über 9,7 Millionen Euro erfolgreich ab
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
Tizeti and Eutelsat Collaborate to Bridge Nigeria’s Digital Divide Capetown, South Africa, With Community Satellite Broadband
Regulatory News:
Eutelsat Communications (Euronext Paris: ETL), the leading satellite operator has inked a deal with Tizeti, West Africa’s pioneer solar-based internet service provider and a
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
RUBIS: Q3 2022 trading update: stable volumes, solid gross profit growth
ROCTOOL: Record attendance for Roctool at K-2022 in Germany
Eurazeo Announces Sale of Majority Ownership Position in NEST New York to North Castle Partners Led Investor Group
Eurazeo, a leading global investment company with a diversified portfolio of €32.5 billion in assets under management, today announced that it has reached an agreement to sell its majority
Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
GEVELOT S.A.: Weekly report of share buyback November 7, 2022
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Transgene Reports Business Update And Q3 2022 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
Successful Launch of EUTELSAT HOTBIRD 13G Satellite
Regulatory News:
Eutelsat Communications (Euronext Paris: ETL) (Paris:ETL) announced that EUTELSAT HOTBIRD 13G satellite was successfully launched into Geostationary Transfer Orbit by American
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that following an interim analysis of
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
GEVELOT S.A.: Weekly report of share buyback October 31, 2022
Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,
Valbiotis präsentiert auf der Jahrestagung der American Association for the Study of Liver Diseases (AASLD) signifikante präklinische Ergebnisse für seinen Wirkstoff TOTUM•448 gegen Fettlebererkrankungen (NAFL und NASH)
Regulatorische Nachrichten:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
Teleperformance Acquires PSG Global Solutions
Regulatory News:
Teleperformance (Paris:TEP), the global leader in outsourced customer and citizen experience management and related digital services, announced today that it has acquired PSG
Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
